Journal updates

  • COVID-19 and impact on peer review

    As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times.  Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.

  • Best article from the June 2020 special issue on Nanomedicines

    New Content ItemRead the best article from the June 2020 issue!

    Summary: Bevacizumab is a monoclonal antibody that specifically inactivates VEGF-A, resulting in a decrease of the development of tumor blood vessels and its growth. Currently, it is employed in the treatment of different types of tumors, particularly colorectal cancer. As for other biologicals, the benefits of bevacizumab are limited by a low capability to penetrate into the tumors that, in addition, may increase the risk of acquiring resistance. In this work, the effect of the nanoencapsulation of bevacizumab (in human serum albumin nanoparticles) was evaluated on a xenograft model of human colorectal cancer.   

    The resulting nanoparticles demonstrated to be more effective in decreasing the glycolysis and metabolic tumor volume than the conventional treatment. This improvement was associated with a significantly higher accumulation of the monoclonal antibody in the tumor tissues when nanoencapsulated in human serum albumin nanoparticles.

    This article was selected as the best article of the Nanomedicines Special Issue by the CRS Nanomedicine and Nanoscale Delivery Focus Group.

  • Inspirational Note on the evolution of drug delivery

    New Content ItemDrug Delivery and Translational Research has published its second Inspirational Note. In this article, Robert Langer and Jeff Hrkach highlight the technological evolution of drug delivery from micro- to nano-, providing examples of approved medicines that demonstrate the significant impact of the drug delivery field in treating many diseases.

  • Featured article: April 2020

    Read the featured article from the April 2020 issue!

    New Content ItemSummary: Treatment of the neurological manifestations of lysosomal storage diseases remains an unmet medical need. BMN 250 is being developed as an enzyme replacement therapy administered directly into the brain ventricles via the intracerebroventricular (ICV) route for treating Sanfilippo type B.  Patients with this rare neurological disease have deficient lysosomal alpha-N-acetylglucosaminidase (NAGLU) enzyme activity. Unlike the ICV route that readily provides biodistribution of therapy to target cells, we show in wild-type and disease animal models that intravenously-administered enzyme does not reach the target neuronal cells. The limited pharmacological response following intravenous administration is likely attributed to the clearance of substrate in endothelial cells that restrict biodistribution to target cells in the brain. Representative staining from superficial medulla oblongata from cynomolgus monkey received BMN 250 via the IV route shows that all NAGLU staining is co-localized with CD31-positive endothelial cells, indicating that IV administered NAGLU does not reach the target neurons. In contrast, NAGLU co-localizes with the neurons following ICV administration.

    The Editorial Board of DDTR selected this article as the best paper of this issue.

  • CRS Nanomedicine and Nanoscale Delivery Focus Group Paper of the Year, 2019

    Congratulations to the authors of Tumor growth inhibition by mSTEAP peptide nanovaccine inducing augmented CD8+ T cell immune responses for being awarded Paper of the Year by the CRS Nanomedicine and Nanoscale Delivery Focus Group.


    New Content Item

    Summary: TumOpen in Tabor antigen-specific cytotoxic T lymphocytes (CTL) directly play a critical role in immunologic tumor inhibition and eradication. To address whether peptide nanovaccine could enhance specific CTL response, we established a syngeneic prostate cancer mouse model with TRAMP-C2  cells, followed by the treatments with either mouse six-transmembrane epithelial antigen of the prostate (mSTEAP) peptides emulsified in incomplete Freund’s adjuvant (IFA) via subcutaneous (SC) injection or nanovaccine carrying an identical amount of mSTEAP peptides via IV or SC injection. Meanwhile, the mouse models were treated with either CD8b mAb followed by nanovaccine treatment, free mSTEAP peptide, or empty PLGA nanoparticles. Immune responses in these mice were examined using cytotoxicity assays at 14 days after treatment. Tumor size and survival in various treatment groups were measured and monitored. The results demonstrated that mSTEAP peptide nanovaccine resulted in tumor inhibition by eliciting a significantly stronger CD8+ T cell immune response when compared with the controls. Moreover, the survival periods of mice treated with mSTEAP nanovaccine were significantly longer than those of mice treated with mSTEAP peptide emulsified in IFA or the treatment controls.
     

    This article will be free to access until May 11, 2020.

  • CRS Oral Drug Delivery Focus Group Paper of the Year, 2019

    The Oral Drug Delivery Focus Group of the Controlled Release Society has awarded the 2019 Paper of the Year award to the paper by Desai et al., Loratadine self-microemulsifying drug delivery systems (SMEDDS) in combination with sulforaphane for the synergistic chemoprevention of pancreatic cancer


    New Content Item Summary: Pancreatic cancer remains refractory to current standards-of-care. Here, we first report that combination of a classical antihistaminic drug, Loratadine (LOR), and a neutraceutical compound, Sulforaphane (SFN), elicits remarkably synergistic chemo-preventive action on pancreatic cancer cells in vitro. However, LOR belongs to BCS class II exhibiting low solubility and high permeability that results in poor oral bioavailability. To address this limitation, we have developed a self-microemulsifying drug delivery system (SMEDDS) formulation carrying LOR, using Quality by Design approach (globule size, 95.13 ± 7.9 nm; PDI, 0.17 ± 0.04), and confirmed that this nanoformulation provides significantly enhanced dissolution profile of LOR in vitro. Further, the nanoformulation, in conjunction with SFN, provided in ~ 7-fold and ~ 11-fold reduction in IC50 values compared to free drug LOR-SFN combination in MIA PaCa-2 and Panc-1 cell lines, respectively. Hence, our studies successfully demonstrate that a unique low-dose combination of LOR encapsulated within SMEDDS with SFN shows significantly enhanced chemo-preventive efficacy in pancreatic cancer.


    This paper will be free to access until May 5, 2020.

  • Check out the first Inspirational Note published in DDTR

    Drug Delivery and Translational Research has published its first Inspirational Note. Inspirational Notes are short review articles covering the development of important medicines and medical devices.  In this article, researchers from the Population Council highlight their experience in ethically bringing safe, effective, and acceptable contraceptive technologies to the world.

  • 2019 DDTR Best Paper of the Year

    Congratulations to the authors of Depletion of collagen by losartan to improve tumor accumulation and therapeutic efficacy of photodynamic nanoplatforms for winning the DDTR Best Paper of the Year award for 2019.


    New Content ItemSummary: It is critical to achieve efficient delivery of photosensitizers throughout the tumor sites in order to obtain therapeutically relevant photodynamic treatment (PDT) efficacy and desired clinical outcomes. However, synthesis and deposition of dense collagen in the tumor extracellular matrix (ECM) result in poor penetration and accumulation of photosensitizer within the tumor tissue. Herein, we develop a losartan pretreatment strategy to deplete tumor collagen, thereby improving the tumor accumulation and PDT efficacy of Chlorine 6 (Ce6) loaded periodic mesoporous organosilica (Ce6-PMO) photodynamic nanoplatform. After pretreatment with losartan in vivo, the tumor collagen I fraction in tumor tissue was significantly reduced by 53% and tumor uptake of Ce6-PMO subsequently administered via peritumoral and intravenous routes was remarkably enhanced. Further, combination of losartan and Ce6-PMO provided the best therapy efficacy, and the suppression rate of tumor volume was measured up to 82%. This study introduces a highly promising synergetic strategy to improve nanoplatform-based PDT efficacy for cancer therapy.

    This paper will be free to access until April 27, 2020.

  • Featured Article: December 2019

    New Content Item

    Galactomannan, a natural polymer, recognized to target macrophage mannose receptors, is reported to induce pro-inflammatory polarization in macrophages, suggesting its possible use as an anti-cancer agent. Hydrazinocurcumin, a pyrazole derivative of curcumin, is reported to exhibit increased anti-cancer efficacy over curcumin. Considering these facts, we synthesized self-assembled galactomannan nanoparticles containing hydrazinocurcumin (PSGM-HCNPs). These nanoparticles re-polarized IL-4 polarized macrophage cells from M2- to M1-like phenotype. Conditioned medium of re-polarized macrophages exhibited anti-metastatic potential and induced apoptosis in cancer cells. PSGM-HCNPs reduced tumor burden, increased survival time, decreased M2- and increased M1-like skewness among ascitic tumor-associated macrophages of tumor-bearing mice.

    The Editorial Board of DDTR selected this article as the best paper of this issue.

  • The 2nd Drug Delivery Conference (July 20-23, 2020)

    The conference focuses on the design, synthesis and clinical validation of new drug delivery vehicles, and is designed to bridge the gap between basic science and unmet clinical needs with a particular focus on gene editing therapeutics, RNA therapeutics, sustained release technologies and immuno-engineering.